Australian government to undertake review of medicines and medical devices regulation

24 October 2014

The Australian government is to carry out a review of the regulation of medicines and medical devices.

The review aims to identify areas of unnecessary, duplicative or ineffective regulation that could be removed or streamlined without undermining the safety or qualities of therapies available in the country, and to provide opportunities to enhance regulatory framework around development, manufacture, marketing and regulation in the sector.

It will be carried out by Lloyd Sansom, Emeritus Professor at the school of pharmacy and medical sciences, University of South Australia, Will Delaat, former chairman of Medicines Australia, and John Horvath, former government chief medical officer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >